# Jiangsu Hengrui Pharmaceuticals Co., Ltd.

# 江蘇恒瑞醫藥股份有限公司

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 1276)**

## OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the "**Company**") had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn) regarding the license agreement entered into between the Company and Glenmark Specialty S.A. on September 24, 2025 (after trading hours, Hong Kong time). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
**Jiangsu Hengrui Pharmaceuticals Co., Ltd.**
**江蘇恒瑞醫藥股份有限公司**
**Mr. Sun Piaoyang**
*Chairman*

Shanghai, PRC
September 24, 2025

*As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Dong Jiahong, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.*

Stock Code: 600276 Stock Abbreviation: Hengrui Pharma No.: Lin 2025-153

# Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement：Entering into License Agreement for Trastuzumab Rezetecan with Glenmark Specialty S.A.

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (江蘇恒瑞醫藥股份有限公司) ("Hengrui" or the "Company") has entered into an agreement with Glenmark Specialty S.A. ("Glenmark Specialty") to grant a paid license of its Class 1 innovative drug Trastuzumab Rezetecan（SHR-A1811）, which is protected by independent intellectual property rights, to Glenmark Specialty.

## I. Basic Information of the Licensed Product

Trastuzumab Rezetecan is the Company's self-developed HER2-targeted ADC. After binding to tumor cells and being internalized, Trastuzumab Rezetecan releases its toxin through protease cleavage within tumor cell lysosomes, inducing cell cycle arrest, ultimately triggering tumor cell apoptosis. The released toxin has high membrane permeability, enabling a bystander killing effect, which further enhances the antitumor efficacy. In May 2025, Trastuzumab Rezetecan was approved in China for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) who have HER2 (ERBB2) activating mutations and have received at least one prior systemic therapy. This is the first self-developed ADC in China that has been approved for patients with HER2-mutant NSCLC. In addition, multiple clinical studies of Trastuzumab Rezetecan are actively ongoing. In August 2025, Trastuzumab Rezetecan in combination with adebrelimab and chemotherapy

obtained Orphan Drug Designation from the US FDA for gastric or gastroesophageal junction adenocarcinoma. In September 2025, the new indication for Trastuzumab Rezetecan in breast cancer was accepted by China's NMPA for review and was included in the priority review program. To date, Trastuzumab Rezetecan has been included in the NMPA's list of breakthrough therapy drugs (突破性治療品種名單) for nine indications, covering NSCLC, breast cancer, gastric or gastroesophageal junction adenocarcinoma, colorectal cancer, biliary tract cancer, and gynecologic malignancies. For other relevant information of Trastuzumab Rezetecan, please refer to the "Jiangsu Hengrui Pharmaceuticals Co., Ltd. Announcement in Relation to Acceptance of Marketing Authorization Application and Inclusion in Priority Review" (Announcement No.: Lin 2025-145) disclosed on the Shanghai Stock Exchange website.

**II. Basic Information of the Counterparty**

Glenmark Specialty is a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.. Glenmark Pharmaceuticals is a research-led, global pharmaceutical company headquartered in Mumbai, India, listed on the National Stock Exchange of India (ticker: GLENMARK) and the Bombay Stock Exchange (ticker: 532296). It has a presence across Branded, Generics, and OTC segments, with a focus on therapeutic areas of respiratory, dermatology and oncology. Glenmark Pharmaceuticals has 11 world-class manufacturing facilities spread across 4 continents, and operations in over 80 countries. Scrip 100 positions Glenmark Pharmaceuticals amongst the Top 100 biopharmaceutical companies ranked by Pharmaceutical Sales in 2023.

**III. Main Terms of the Agreement**

Licensor: Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Licensee: Glenmark Specialty S.A.

**A. Scope of License**

Hengrui has granted Glenmark Specialty exclusive rights to develop and commercialize Trastuzumab Rezetecan worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan.

**B. Financial Terms**

1. Upfront Payment

Glenmark Specialty will pay Hengrui an upfront payment of US $18 million.

2. Milestone Payments

Hengrui is eligible to receive regulatory and commercial milestone payments of up to US $1.093 billion.

3. Sales Royalties

Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark Specialty will pay corresponding royalties to Hengrui.

**C. Joint Product Development and Commercialization Committee**

Hengrui and Glenmark Specialty will establish a joint product development and commercialization committee to coordinate the global development and commercialization of the licensed product. Each party will appoint an equal number of representatives, not exceeding two from each party.

**D. Terms of the Agreement**

The license agreement between Hengrui and Glenmark Specialty will take effect upon execution by both parties. Unless terminated earlier in accordance with the terms of the Agreement or otherwise renewed pursuant to mutual agreement of both parties, the Agreement will remain in force until the expiration of the royalty term for Trastuzumab Rezetecan.

**E. Governing Law**

This Agreement shall be governed by and interpreted in accordance with the laws of Singapore.

**IV. Benefits of the Deal to the Company**

The signing of this agreement will help expand the international market for Trastuzumab Rezetecan, providing high-quality treatment options for patients worldwide. It will also further enhance the Company's innovative brand and international performance. The Company adheres to the dual strategy of independent R&D and open collaboration. While pursuing organic growth, it actively strengthens international partnerships to accelerate the translation of R&D achievements. By leveraging the global reach of international leading partners, the Company aims to extend its presence in overseas markets, integrate more deeply into the global pharmaceutical innovation network, and maximize product value—ultimately bringing its innovative therapies to patients around the world.

**V. Risk Warning**

The development, clinical trial approval, and commercialization of products involve long cycles and numerous stages. Drug R&D and eventual market launch are subject to various uncertainties. Therefore, there are inherent risks as to whether Trastuzumab Rezetecan will ultimately obtain regulatory approval and be successfully marketed overseas. In addition, the future success-based milestone payments stipulated in the Agreement are conditional, and the final amounts of such payments remain uncertain. Investors are kindly advised to make prudent decisions and pay attention to investment risks. The Company will continue to fulfill its information disclosure obligations on time in accordance with relevant regulations and will provide updates on the progress of the project as appropriate.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

September 24, 2025